Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampVerona Pharma plcargenx SE
Wednesday, January 1, 201418022744241601.57
Thursday, January 1, 201525127615392385.38
Friday, January 1, 201628944887370036.73
Sunday, January 1, 2017809627414970357
Monday, January 1, 2018798522931413266
Tuesday, January 1, 2019899459772279461
Wednesday, January 1, 202029772000183907682
Friday, January 1, 202133907000307644000
Saturday, January 1, 202226579000472132000
Sunday, January 1, 202349868547709539000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of two prominent companies: argenx SE and Verona Pharma plc, from 2014 to 2023. Over this period, argenx SE has seen a staggering increase in SG&A expenses, growing by over 16,000%, reflecting its aggressive expansion and investment in research and development. In contrast, Verona Pharma plc's expenses have grown by approximately 2,700%, indicating a more conservative growth strategy. Notably, in 2023, argenx SE's expenses were nearly 15 times higher than those of Verona Pharma plc, highlighting its significant market presence. This data provides a fascinating insight into how different strategic approaches can impact financial outcomes in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025